Merck Announces HPS2-THRIVE Study of TREDAPTIVE™ (Extended-Release Niacin/Laropiprant) Did Not Achieve Primary Endpoint

  Merck Announces HPS2-THRIVE Study of TREDAPTIVE™ (Extended-Release
  Niacin/Laropiprant) Did Not Achieve Primary Endpoint

Business Wire

WHITEHOUSE STATION, N.J. -- December 20, 2012

Merck (NYSE:MRK), known outside the United States and Canada as MSD, today
announced that the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to
Reduce the Incidence of Vascular Events) study of
TREDAPTIVE^™(extended-release niacin/laropiprant) did not meet its primary
endpoint. Merck and the investigators are informing regulatory agencies of
these results. The company is also preparing communications to health care
providers in countries where the medicine is currently available, and will
continue to work with regulators to provide updated information to health care
providers. Based on the current understanding of these new data and until
further analyses can be completed, Merck is recommending that providers not
start new patients on TREDAPTIVE. Merck does not plan to seek regulatory
approval for the medicine in the United States.

HPS2-THRIVE was independently conducted by the Clinical Trial Service Unit at
Oxford University and funded by Merck. The study enrolled 25,673 patients
considered to be at high risk for cardiovascular events. Of those enrolled,
14,741 were from Europe (the United Kingdom and Scandinavia) and 10,932 were
from China. Patients in the study were followed for a median of 3.9 years.
HPS2-THRIVE compared extended -release niacin and laropiprant plus statin
therapy versus statin therapy. It was not designed to assess directly the
separate effects of either extended-release niacin or laropiprant.

In the study, adding the combination of extended-release niacin and
laropiprant to statin therapy did not significantly further reduce the risk of
the combination of coronary deaths, non-fatal heart attacks, strokes or
revascularizations compared to statin therapy. In addition, there was a
statistically significant increase in the incidence of some types of non-fatal
serious adverse events in the group that received extended-release
niacin/laropiprant.

With the agreement of the independent research team at Oxford University,
Merck is sharing results from the study with regulatory agencies in countries
where the medicine is approved (under the brand names TREDAPTIVE or
CORDAPTIVE) and in other countries as well. The investigators are conducting
additional analyses, including regional analyses, to further understand the
results. They anticipate reporting the detailed study results in the first
quarter of 2013.

"While we are disappointed in these results, we thank the investigators who
have conducted the study and the patients who have participated in it,” said
Peter S. Kim, Ph.D., president, Merck Research Laboratories. “We are committed
to working closely with the independent research team at Oxford University and
with regulatory agencies to understand the results and determine next steps."

About TREDAPTIVE/CORDAPTIVE

TREDAPTIVE/CORDAPTIVE has been approved in approximately 70 countries,
including in Europe, and is sold in approximately 40 countries. TREDAPTIVE is
also sold under the brand names PELZONT in Italy and TREVACLYN in Italy and
Portugal. Sales through the first three quarters of 2012 were approximately
$13 million.

About Merck

Today's Merck is a global healthcare leader working to help the world be well.
Merck is known as MSD outside the United States and Canada. Through our
prescription medicines, vaccines, biologic therapies, and consumer care and
animal health products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching

policies, programs and partnerships. For more information, visit www.merck.com
and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially from those set
forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest rate
and currency exchange rate fluctuations; the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory
approval; Merck’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of Merck’s
patents and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those
described in the forward-looking statements can be found in Merck’s 2011
Annual Report on Form 10-K and the company’s other filings with the Securities
and Exchange Commission (SEC) available at the SEC’s Internet site
(www.sec.gov).

Contact:

Merck
Media Contacts:
Pamela Eisele, 908-423-5042
Skip Irvine, 267-305-5397
or
Investor Contact:
Carol Ferguson, 908-423-4465
 
Press spacebar to pause and continue. Press esc to stop.